Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMZ/LOM vs TMZ for Newly Diagnosed MGMT Methylated Glioblastoma
NCT06419946Phase 3Recruiting
- Sponsor
- Region Västra Götaland
- Start
- Feb 2025
- Primary completion
- Dec 2031
- Modality
- DNA Intercalators/Alkylators
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of lomustine in glioblastoma (GBM) and Gliosarcoma (GS) (2 arms), sponsored by Region Västra Götaland. Primary endpoint: Overall Survival at 36 months. Started Feb 2025; status: recruiting.
02
Drugs
lomustine
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT06419946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06419946.